Current status and future perspectives for the treatment of resectable locally advanced esophagogastric junction cancer: A narrative review

doi:10.3748/wjg.v29.i24.3758

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 24

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2805)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-5) series.

Item

Count

PDF

WORD

HTML

2016

Tables (1-5)

222

Sum=2305

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

119

Download

222

Sum=341

Jun 28, 2023 (publication date) through Jun 14, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Jun 28, 2023; 29(24): 3758-3769
Published online Jun 28, 2023. doi: 10.3748/wjg.v29.i24.3758

Table 1 Patients with Siewert type I esophagogastric junction adenocarcinoma who underwent surgery at our institute

n	35
Male	34 (97.1%)
Age (yr)	67 (42-79)
Field of LN dissection 2/3	2/33
Open/MIE/Robot assisted	6/24/5
Preoperative chemotherapy	4 (11.4%)
Tumor size (mm)	35.3 (9-110)
Esophageal invasion length (mm)	30 (18-110)
pT 1a/1b/2/3/4a/4b¹	4/10/3/18/0/0
pN 0/1/2/3¹	15/4/4/12
pM 0/1¹	30/5
pStage IA/IB/IIA/IIB/IIIA/IIIB/IVA/IVB¹	3/7/2/6/0/4/8/5
Upper mediastinal LN metastasis	11/35 (31.4%)
Middle mediastinal LN metastasis	10/34 (29.4%)
Lower mediastinal LN metastasis	11/32 (34.4%)
Recurrence	14 (40.0%)
Site of recurrence²
Liver	5
Adrenal gland	5
Distant LN	3
Peritoneum	2
Bone	2
Pleura	1
Pancreas	1

¹Classified by the 8^th edition of the Union for International Cancer Control (UICC)-Tumor Node Metastasis (TNM) classification.

²Including overlapped cases.

EGJAC: Esophagogastric adenocarcinoma; LN: Lymph node; MIE: Minimally invasive esophagectomy.

Citation: Shoji Y, Koyanagi K, Kanamori K, Tajima K, Ogimi M, Yatabe K, Yamamoto M, Kazuno A, Nabeshima K, Nakamura K, Nishi T, Mori M. Current status and future perspectives for the treatment of resectable locally advanced esophagogastric junction cancer: A narrative review. World J Gastroenterol 2023; 29(24): 3758-3769
URL: https://www.wjgnet.com/1007-9327/full/v29/i24/3758.htm
DOI: https://dx.doi.org/10.3748/wjg.v29.i24.3758